Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome in North America.
Amer J Gastroenterol, 97 (2002), pp. S1-S5
[2.]
A.P. Manning, W.G. Thompson, K.W. Heaton, et al.
Towards a positive diagnosis of the irritable bowel.
Br Med J, 2 (1978), pp. 653-654
[3.]
W.G. Thompson, G.F. Longstreth, D.A. Drossman, et al.
Functional bowel disorders and functional abdominal pain.
Gut, 45 (1999), pp. 43-47
[4.]
S.J. Vanner, W.T. Depew, W. Paterson, L.R. Lacosta, A.G. Groll, J.B. Simon, et al.
Predictive value of the Roma criteria for diagnosing the irritable bowel syndrome.
Am J Gastroenterol, 94 (1999), pp. 2912-2917
[5.]
W.G. Thompson.
Irritable bowel syndrome: prevalence, prognosis and consequences.
CMAJ, 134 (1986), pp. 111-113
[6.]
G.F. Longstreth, G. Wolde-Tsadik.
Irritable bowel-type symptoms in HMO examinees: prevalence, demographics and clinical correlates.
Dig Dis Sci, 38 (1993), pp. 1581-1589
[7.]
G. Bommelaer, M. Rouch, M. Dapoigny, D. Pais, P. Loisy, M. Gaylino, et al.
Epidemiology of functional bowel disorders in apparently healthy people.
Gastroenterol Clin Biol, 10 (1986), pp. 7-12
[8.]
G.W. Welch, E.W. Pomare.
Functional gastrointestinal symptoms in a Wellington community sample.
NZ Med J, 103 (1990), pp. 418-420
[9.]
L. Kay, T. Jorgensen, K.H. Jensen.
The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors.
J Intern Med, 236 (1994), pp. 23-30
[10.]
W. Bi-Zhen, P. Qi-Ying.
Functional bowel disorders in apparently healthy Chinese people.
Chinese J Epidemiol, 9 (1988), pp. 345-349
[11.]
D.A. Drossman, Z. Li, E. Andruzzi, et al.
US householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact.
Dig Dis Sci, 38 (1993), pp. 1569-1580
[12.]
M.J. Zuckerman, L.G. Guerra, D.A. Drossman, J.A. Foland, G.G. Gregory.
Comparison of bowel patterns in Hispanics and non-Hispanic whites.
Dig Dis Sci, 40 (1995), pp. 1761-1769
[13.]
A.P.S. Hungin, P.J. Whorwell, J. Tack, F. Mearin.
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40.000 subjects.
Aliment Pharmacol Ther, 17 (2003), pp. 643-650
[14.]
C.M. Mitchell, D.A. Drossman.
Survey of the AGA membership relating to patients with functional gastrointestinal disorders.
Gastroenterology, 92 (1987), pp. 1282-1284
[15.]
N.J. Talley, A.R. Zinsmeister, C. Van Dyke, L.J. Melton III.
Epidemiology of colonic symptoms and the irritable bowel syndrome.
Gastroenterology, 101 (1991), pp. 927-934
[16.]
R. Jones, S. Lydeard.
Irritable bowel syndrome in the general population.
BMJ, 304 (1992), pp. 87-90
[17.]
B.L.J. Mendis, B.C. Wijesiriwardena, J.H.R. Sheriff, K. Dharmadasa.
Irritable bowel syndrome.
Ceylon Med J, 27 (1982), pp. 171-181
[18.]
D.T. Sobral, K.S. Vidigal, K. Farias e Silva.
Síntomas digestivos em jovens: inquérito em estudantes de medicina.
Arq Gastroenterol (Sao Paolo), 28 (1991), pp. 27-32
[19.]
F.A. Quilici, SB. André.
Um consenso nacional: síndrome do intestino irritável.
[20.]
L.A. Ángel, A. Amaya, C. Perilla, A. Góngora, A. Sánchez, C. Bohórquez, et al.
Prevalencia del síndrome de intestino irritable y factores asociados.
Acta Med Col, 22 (1997), pp. 219-224
[21.]
I. Huerta, M.A. Valdovinos, M. Schmulson.
Irritable bowel syndrome in México.
Dig Dis, 19 (2001), pp. 251-257
[22.]
M.A. Tanimoto, M. Schmulson, D. Ramírez, M.A. Valdovinos.
Prevalencia de trastornos funcionales digestivos en estudiantes de medicina.
Rev Gastroenterol Mex, 60 (1995), pp. 57
[23.]
R. Toma, B. Iade.
Frecuencia del síndrome de intestino irritable en una población de Montevideo. Montevideo: Hospital de Clínicas «Dr Manuel Quintela», Escuela de Graduados, Clínica de Nutrición y Digestivo.
Profesor D.r. Elbio Zevallos, agosto de, (2000),
[24.]
M.J. Schmulson, M.A. Valdovinos.
Utilización de recursos médicos por los pacientes con síndrome de intestino irritable en un hospital de tercer nivel.
Rev Gastroenterol Mex, 63 (1998), pp. 6-10
[25.]
M. Schmulson, J.M. Remes, T. Olivas, M.A. Valdovinos, C. Hinojosa, L. Chang, et al.
Clinical characteristics and QOL in IBS patients from Mexico and the USA: are they different?.
Gastroenterology, 124 (2003), pp. A395
[26.]
J.F. Fieling.
Surgery and the irritable bowel syndrome: the singer as well as the song.
J Ir Med, 76 (1988), pp. 33-34
[27.]
J.M. Remes, M.A. Valdovinos, C. Hinojosa, M.J. Schmulson.
IBS patients differ according to age: self-reported symptom severity is related.
Am J Gastroenterol, 98 (2003), pp. 5268
[28.]
C.F. Francisconi, U. Meneghelli, F. Quilici, M.T. Haddad, S. André.
A comparison of how gastroenterologists (GE) and internists (INT) evaluate patients with irritable bowel syndrome (IBS).
Gut, 45 (1999), pp. A340
[29.]
M.C. Bojórquez, A. Larrosa, E.O. Martínez.
Dolor abdominal crónico (DAC) en niños: ¿síndrome de intestino irritable (SII) versus dispepsia no ulcerosa (DNU)?.
Rev Gastroenterol Méx, 65 (2000), pp. A52
[30.]
D.A. Drossman, W.E. Whitehead, M. Camilleri.
Irritable bowel syndrome: a technical review for practice guideline development.
Gastroenterology, 112 (1997), pp. 2120-2137
[31.]
H. Mertz.
Review article: visceral hypersensitivity.
Aliment Pharmacol Ther, 17 (2003), pp. 623-633
[32.]
H. Mertz.
Altered CNS processing of visceral pain in IBS.
Irritable bowel syndrome diagnosis and treatment, pp. 55-68
[33.]
M. Camilleri, M-G. Choi.
Irritable bowel syndrome.
Aliment Pharmacol Ther, 11 (1997), pp. 3-15
[34.]
D.H.S. Silverman, J.A. Munakata, H. Ennes, et al.
Regional cerebral activity in normal and pathologic perception of visceral pain.
Gastroenterology, 112 (1997), pp. 64-72
[35.]
R. Quera, J. Valenzuela.
Hipersensibilidad visceral: un concepto a nuestro alcance.
Rev Med Chile, 131 (2003), pp. 85-92
[36.]
M.J. Schmulson, M.A. Valdovinos, P. Milke.
Chili pepper and rectal hyperalgesia in irritable bowel syndrome.
Am J Gastroenterol, 98 (2003), pp. 1214-1215
[37.]
J. Serra, F. Azpiroz, J.R. Malagelada.
Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome.
Gut, 48 (2001), pp. 14-19
[38.]
R.C. Spiller.
Postinfectious irritable bowel syndrome.
Gastroenterology, 124 (2003), pp. 1662-1671
[39.]
D.A. Drossman.
Psychosocial aspects of the functional gastrointestinal disorders.
Neurogastroenterology, pp. 33-40
[40.]
D.A. Drossman, J. Leserman, G. Nachman, et al.
Sexual and physical abuse in women with functional or organic gastrointestinal disorders.
Ann Intern Med, 113 (1990), pp. 828-833
[41.]
N.J. Talley, S.L. Fett, A.R. Zinsmeister, L.J. Melton III.
Gastrointestinal tract symptoms and self-report abuse: a population based study.
Gastroenterology, 107 (1994), pp. 1040-1049
[42.]
W.E. Whitehead, O.S. Palsson.
Is pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception.
Gastroenterology, 115 (1998), pp. 1263-1271
[43.]
F. Creed.
Psychopatology of the functional disorders of the gut.
Functional disorders of the gut,
[44.]
B.A. Hahn, L.J. Kirchdoerfer, S. Fullerton, et al.
Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization, and quality of life.
Aliment Pharmacol Ther, 11 (1997), pp. 553-559
[45.]
R.F. Yacavone, I.I.I. Locke GR, D.T. Provenzale, G.M. Eisen.
Quality of Life measurement in gastroenterology: what is available?.
Am J Gastroenterol, 96 (2001), pp. 285-297
[46.]
M. Schmulson, O.Y. Lee, L. Chang, et al.
Symptom differences in moderate to severe IBS patients based on predominant bowel habit.
Am J Gastroenterol, 94 (1999), pp. 2929-2935
[47.]
M.A. Testa, D.C. Simonson.
Assessment of quality of life outcomes.
N Engl J Med, 334 (1966), pp. 835-840
[48.]
I.K. Wiklund, H. Glise.
Quality of life in different gastrointestinal conditions.
Eur J Surg Suppl, 582 (1998), pp. 56-61
[49.]
A.L. Steward, S. Greenfield, R.D. Hays, et al.
Functional status and well being of patients with chronic conditions: results from the medical outcomes study.
JAMA, 262 (1989), pp. 907-913
[50.]
J.P.P. Moraes-Filho.
Doenças funcionais do aparelho digestivo: a importância 2 distúrbios emocionais na gênese dos sintomas.
Rev Bras Med, 51 (1994), pp. 1395-1404
[51.]
H.B. El-Serag.
Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life.
Rev Gastroenterol Dis, 3 (2003), pp. 3-11
[52.]
H.B. El-Serag, K. Olden, D. Bjorkman.
Health-related quality of life among persons with irritable bowel syndrome: a systematic review.
Aliment Pharmacol Ther, 16 (2002), pp. 1171-1185
[53.]
D.A. Drossman, W.E. Whitehead, B.B. Toner, et al.
What determines severity among patients with painful functional bowel disorders.
Am J Gastroenterol, 95 (2000), pp. 974-980
[54.]
N.E. Wells, B.A. Hahn, P.J. Whorwell.
Clinical economical review: irritable bowel syndrome.
Aliment Pharmacol Ther, 11 (1997), pp. 1019-1030
[55.]
P.P. Patel, A. Petita, R. Fogel, et al.
The economic impact of irritable bowel syndrome in a managed care setting.
J Clin Gastroenterol, 35 (2000), pp. 14-20
[56.]
N.J. Talley, S.F. Philips, L.J. Melton, et al.
Diagnostic value of the Manning criteria in irritable bowel syndrome.
Gut, 31 (1990), pp. 77
[57.]
M.W. Schmulson, L. Chang.
Diagnostic approach to the patient with irritable bowel syndrome.
Am J Med, 107 (1999), pp. 205
[58.]
Thompson WG, Longstreth G, Drossman DA, et al. En: Rome II: the functional gastrointestinal disorders. 2nd ed. p. 335-408.
[59.]
R.B. Lynn, L.S. Friedman.
Irritable bowel syndrome.
N Engl J Med, 329 (1993), pp. 1940
[60.]
E.T. Swarbrick, L. Bat, J.E. Hegarty, et al.
Site of pain from the irritable bowel.
Lancet, 2 (1980), pp. 443
[61.]
A.M. Connell, C. Hilton, G. Irvine, et al.
Variation of bowel habits in two population samples.
Br Med J, 2 (1965), pp. 1095
[62.]
P.J. Whorwell, M. McCallum, F.H. Creed, C.T. Roberts.
Non-colonic features of irritable bowel syndrome.
Gut, 27 (1986), pp. 37-40
[63.]
A.M. White, W.H. Stevens, A.R. Upton, et al.
Airway responsiveness to inhaled metacholine in patients with irritable bowel syndrome.
Gastroenterology, 100 (1991), pp. 68-74
[64.]
J.I. Hudson, D.L. Goldenberg, H.G. Pope, et al.
Comorbidity of fibromyalgia with medical and psyquiatric disorders.
Am J Med, 92 (1992), pp. 363
[65.]
S.J. Vanner, W.T. Depew, W.G. Paterson, et al.
Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome.
Am J Gastroenterol, 94 (1999), pp. 2912
[66.]
L.J. Brandt, D. Bjorkman, M.B. Fennerty, et al.
Systematic review on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. S7-S26
[67.]
D.A. Drossman, W.E. Whitehead, M. Camillieri.
Irritable bowel syndrome: a technical review for practice guideline development.
Gastroenterology, 112 (1997), pp. 2120-2137
[68.]
W. Curioso, D. Mendoza.
Prevalencia y asociación de la dispepsia y el síndrome de intestino irritable en una comunidad de la selva peruana.
Rev Gastroent Perú, 22 (2002), pp. 129-140
[69.]
W.J. Katon, M. Von Korff, E. Lin.
Panic disorder: relationship to high medical utilization.
Am J Med, 92 (1992), pp. 7S
[70.]
D.A. Drossman, W.G. Thompson.
The irritable bowel syndrome: review and a graduated multi-component treatment approach.
Ann Intern Med, 116 (1992), pp. 1009
[71.]
R.A. Awad, V.H. Cordova, M. Dibildox, et al.
Reduction of post prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.
Acta Latinoamer Gastroenterol, 27 (1997), pp. 247-251
[72.]
R. Bulat, C. Caldarelli, G. Tougas.
Therapeutic utility of antispasmodics in IBS.
Irritable bowel syndrome diagnosis and treatment, pp. 173-178
[73.]
R. Awad, M. Dibildox, F. Ortiz.
The irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized, double blind placebo-controlled trial.
Acta Gastroenterol Latinoam, 25 (1995), pp. 137-144
[74.]
T. Poynard, S. Naveau, B. Mory, J.C. Chaput.
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.
Aliment Pharmacol Ther, 8 (1994), pp. 499-510
[75.]
T. Poynard, C. Regimbeau, Y. Benhamou.
Meta-analysis of smooth muscle relevants in the treatment of irritable bowel syndrome.
Aliment Pharm Ther, 15 (2001), pp. 355-361
[76.]
J. Jailwala, T. Imperiale, K. Kroenke.
Pharmacologic management of IBS. A systematic review of randomized controlled trials.
Ann Intern Med, 133 (2000), pp. 136-147
[77.]
S.J.O. Veldhuyzen van Zante, N.J. Talley, P. Bytzer, K.B. KLein, O.J. Whorwell, A.R. Zinsmeister.
Design of treatment trials for functional gastroeintestinal disorders.
Gut, 45 (1999), pp. 1169-1177
[78.]
R. Akehurst, E. Kaltenhaler.
Treatment of irritable bowel syndrome: review of randomized controlled trials.
Gut, 48 (2001), pp. 272-282
[79.]
N. Talley.
Pharmacologic therapy for the irritable bowel syndrome.
Am J Gastroenterol, 98 (2003), pp. 750-758
[80.]
D.P. Burkitt, A.R.P. Walker, N.S. Painter.
Effect of dietary fiber on stools and transit times and its role in the causation of disease.
Lancet, 2 (1971), pp. 1408-1411
[81.]
E. Bright-See, G.E. MacKeown-Eysson.
Estimation of per capita crude and dietary fiber supply in 38 countries.
Am J Clin Nutr, 39 (1984), pp. 821-829
[82.]
R. Vincent, A. Roberts, M. Frier.
Effect of bran particle size on gastric emptying and bowel transit in humans: a scintigrafic study.
Gut, 37 (1995), pp. 216-219
[83.]
A. MacIntyre, R.M. Vincent, A.C. Perkins, R.C. Spiller.
Effect of bran, ispaghula and inert plastic particles on gastric emptying and small bowel transit in humans.
Gut, 40 (1997), pp. 223-227
[84.]
G.F. Longstreth, D.D. Fox, L. Youkeles, A.B. Forsythe, D.A. Wolochow.
Psyllium therapy in the irritable bowel syndrome. A double-blind trial.
Ann Intern Med, 95 (1981), pp. 53-56
[85.]
M. Tomás, R. Anon, M. Mínguez.
The efficacy of Platago ovata as a regulator of intestinal transit. A double-blind study compared to placebo.
Rev Esp Enferm Dig, 82 (1992), pp. 511-514
[86.]
S. Arffmann, J.R. Andersen, J. Hegnhoj, D.M.O. Schaffalitzky, N.B. Mogensen.
The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind crossover study.
Scand J Gastroenterol, 20 (1985), pp. 295-298
[87.]
J. Snook, H.A. Shepherd.
Bran supplementation in the treatment of the irritable bowel syndrome.
Aliment Pharmacol Ther, 8 (1994), pp. 511-514
[88.]
M.R. Lucey, M.L. Clark, J. Lowndes, A.M. Dawson.
Is bran efficacious in the irritable bowel syndrome? A double blind placebo controlled crossover study.
Gut, 28 (1987), pp. 221-225
[89.]
P.B. Mortensen, J.R. Andersen, S. Arffmann, E. Krag.
Shortchain fatty acids and the irritable bowel syndrome: the effect of wheat bran.
Scand J Gastroenterol, 22 (1987), pp. 185-192
[90.]
J. Soltoft, B. Krag, E. Gudmand-Hoyer, E. Kristensen, H.R. Wulff.
A double-blind trial of the effect of wheat bran on symptoms of the irritable bowel syndrome.
Lancet, 1 (1976), pp. 270-272
[91.]
S. Fowlie, M.A. Eastwood, R. Prescott.
The irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fiber supplementation.
J Psychosom Res, 36 (1992), pp. 175-180
[92.]
I.J. Cook, E.J. Irvine, D. Campbell, S. Shannon, S.N. Reddy, S.M. Collins.
Effect of dietary fiber on symptoms and rectosigmoid motility in patients with the irritable bowel syndrome. A controlled crossover study.
Gastroenterology, 98 (1990), pp. 66-72
[93.]
P.P. Toskes, K.L. Connery, T.W. Ritchey.
Calcium polycarbophil compared with placebo in the irritable bowel syndrome.
Aliment Pharmacol Ther, 7 (1993), pp. 87-92
[94.]
A. Jalihal, G. Kurian.
Ispaghula therapy in the irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction.
J Gastroenterol Hepatol, 5 (1990), pp. 507-513
[95.]
A. Prior, P.J. Whorwell.
Double blind study of ispaghula in the irritable bowel syndrome.
Gut, 28 (1987), pp. 1510-1537
[96.]
T. Hallgren, S. Fath, D.S. Delbro, et al.
Loperamide improves sphincter function and continence after restorative proctocolectomy.
Dig Dis Sci, 39 (1994), pp. 2612-2618
[97.]
E. Ayala, R. Barúa León.
Asociación entre síndrome de intestino irritable y síndrome depresivo.
Rev Gastroent Perú, 21 (2001), pp. 198-204
[98.]
M. Read, N.W. Read, D.C. Barber, H.L. Duthie.
Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency.
Dig Dis Sci, 27 (1982), pp. 807-814
[99.]
R.A. Awad, F. Llorens, A.L. Camelo, M. Sánchez.
A randomized double-blind placebo-controlled trial of lidamidin HCL in irritable bowel syndrome.
Acta Gastroenterol Latinoam, 30 (2000), pp. 169-175
[100.]
A. Rodríguez, T. Valdez, F. Llorens.
Tratamiento del colon irritable con lidamidina y psicoterapia de apoyo.
Rev Gastroenterol Mex, 62 (1997), pp. 7-13
[101.]
M. Camilleri, D-Y Kim, S. McKinzie, et al.
Clonidine in diarrea- predominant irritable bowel syndrome: a ramdomized, placebo-controlled, dose response study.
Gastroenterology, 122 (2002), pp. A59
[102.]
I.G. Egbunike, BJ. Chaffeé.
Antidepressants in the management of chronic pain syndromes.
Pharmacotherapy, 10 (1990), pp. 262-270
[103.]
K.B. Klein.
Controlled treatment trials in the irritable bowel syndrome: a critique.
Gastroenterology, 95 (1988), pp. 232-241
[104.]
R.E. Clouse, P.J. Lustman, R.A. Geisman, et al.
Antidepressant therapy in 138 patients with irritable bowel syndrome: a five year clinical experience.
Aliment Pharmacol Ther, 8 (1994), pp. 409-416
[105.]
J. Jailwala, P.F. Imperiale, K. Kroenke, et al.
Pharmacology treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials.
Ann Int Med, 133 (2000), pp. 136-147
[106.]
J.L. Jackson, P.G. O'Malley, G. Tomkins, et al.
Treatment of functional gastrointestinal disorders with antidepressant medications. A meta-analysis.
Am J Med, 108 (2000), pp. 65-72
[107.]
American College of Gastroenterology, Functional Gastrointestinal Disorders Task Force.
Evidence-based position statement on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. 1S-5S
[108.]
N. Talley.
Serotoninergic neuroenteric modulators.
Lancet, 358 (2001), pp. 2061-2064
[109.]
L.X. Cubeddu.
Serotonin mechanisms in chemoterapy-induced emesis in cancer patients.
Oncology, 53 (1996), pp. 18-25
[110.]
J.J. Galligan.
Motility and pharmacologic therapies. Schuster atlas of gastrointestinal motiliy in health and disease 2 nd e.d. BC Decker Inc.
Hamilton, (2002), pp. 399-410
[111.]
M. Camilleri, A.R. Northcutt, S. Kong.
Efficacy and safety of alosetron in women with irritable bowel syndrome.
Lancet, 355 (2000), pp. 1035
[112.]
K. Olden, R.G. DeGarmo, P. Jhingran, B. Bagby, C. Decker, M. Markowitz, et al.
Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Amer J Gastroenterol, 97 (2002), pp. 3139-3145
[113.]
S. Caras, G. Krause.
Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome.
Gastroenterology, 120 (2001), pp. A217
[114.]
J. Bockaert, L. Fagni, A. Dumuis.
5HT4 receptors: an update.
Handbook Exp Pharmacol, 129 (1997), pp. 439-474
[115.]
J. Fioramonti, M. Million, L. Bueno.
Investigations on a 5-HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying [resumen].
Gastroenterology, 114 (1998), pp. A752
[116.]
H-J Pfannkuche, T. Jul, R. Gamse, D. Hoyer, H. Mattes, K-H. Buchheit.
The properties of the new prokinetically active drug. SDZ HTF 919 [resumen].
Neurogastroenterol Mot, 7 (1995), pp. 280
[117.]
C.M. Prather, M. Camilleri, A.R. Zinsmeister, et al.
Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome.
Gastroenterology, 118 (2000), pp. 463-468
[118.]
S. Muller-Lissner, I. Fumagalli, K.D. Bardhan, et al.
Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
Aliment Pharmacol Ther, 15 (2001), pp. 1655-1666
[119.]
M.P. Lefkowitz, Y. Shi, C. Schmitt, et al.
The 5HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome [resumen 396].
Am J Gastroenterol, 94 (1999), pp. 2676
[120.]
J. Novick, P. Miner, R. Krause, K. Glebas, H. Bliesath, G. Ligozio, et al.
A randomized, double blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
Aliment Pharmacol Ther, 16 (2002), pp. 1877-1888
[121.]
J. Kellow, O. Lee, F.Y. Chang, S. Thongsawat, M.Z. Mazlam, H. Yuen, et al.
An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
Gut, 52 (2003), pp. 671-676
[122.]
H. Nyhlin, C. Bang, L. Elsborg, et al.
Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population.
Gastroenterology, 124 (2003), pp. A389
[123.]
Study #307 Data on file. Novartis Pharmaceuticals Corporation.
[124.]
M. Camilleri.
Management of the irritable bowel syndrome.
Gastroenterology, 120 (2001), pp. 652-668
[125.]
The Latin America Investigation Group of Tegaserod: Uzcanga L Cohen V.
Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (I.B.S.
-C) Gastroenterology, 123 (2003), pp. A571
[126.]
D.A. Drossman, M. Camilleri, E. Mayer, et al.
AGA technical review on irritable bowel syndrome.
Gastroenterology, 123 (2002), pp. 2108-2131
[127.]
M. Camilleri.
Management of the irritable bowel syndrome.
Gastroenterology, 120 (2001), pp. 652-668
[128.]
W.E. Whitehead, M.D. Crowell, J.C. Robinson, et al.
Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared to subjects without bowel dysfunction.
Gut, 33 (1992), pp. 825-830
[129.]
L.J. Brandt, D. Bjorkman, M.B. Fennerty, et al.
Systematic review on the management of irritable bowel syndrome in North America.
Am J Gastroenterol, 97 (2002), pp. 1-26
[130.]
S.J.O. Veldhuyzen van Zanten, N.J. Talley, P. Bytzer, et al.
Design of treatment trials for functional gastrointestinal disorders.
Gut, 45 (1999), pp. 1169-1177
[131.]
D.A. Drossman, B. Toner, W. Whitehead, et al.
A multi-center randomized trial of cognitive-behavioral treatment (CBT) versus education (EDU) in moderate to severe functional bowel disorder (FBD).
Gastroenterology, 124 (2003), pp. A530
[132.]
R. Lea, L.A. Houghton, E.L. Calvert, et al.
Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome.
Aliment Pharmacol Ther, 17 (2003), pp. 635-642
[133.]
W.M. Gonzalkorale, V. Miller, A. Afzal, P.J. Whorwell.
Long term benefits of hypnotherapy for irritable bowel syndrome.
Gut, 52 (2003), pp. 1623-1629
[134.]
E. Quigley, L. O'Mahony, J. McCarthy, P. Kelly, J.K. Collins, F. Shanahan, et al.
Probiotics for the irritable bowel syndrome (IBS): a randomized, double blind, placebo-controlled comparison of lactobacillus and bifidobacterium strains.
Gastroenterology, 122 (2002), pp. A59
[135.]
M.A. O'Sullivan, C.A. O'Morain.
Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo- controlled crossover study.
Dig Liver Dis, 32 (2000), pp. 302-304
[136.]
N.W. Read, J.L. Abitbol, K.D. Bardhan, P.J. Whorwell, B. Fraitag.
Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.
Gut, 41 (1997), pp. 664-668
[137.]
M. Dapoigny, J.L. Abitbol, B. Fraitag.
Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.
Dig Dis Sci, 40 (1995), pp. 2244-2249
[138.]
J.R. Mathias, M.H. Clench, T.L. Abell, et al.
Effect of leuprolide acetate in treatment of abdominal pain and nausea in pre menopausal women with functional bowel disease: a doubleblind, placebo-controlled, randomized study.
Dig Dis Sci, 43 (1998), pp. 1347-1355
[139.]
Farthing MJG.
New drugs in the management of the irritable bowel syndrome.
Drugs, 56 (1998), pp. 11-21
[140.]
A. Bensoussan, N.J. Talley, M. Hing, R. Menzies, A. Guo, M. Ngu.
Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.
JAMA, 280 (1998), pp. 1585-1589
[141.]
M. Pittler, E. Ernst.
Peppermint for irritable bowel syndrome: a critical review and metaanalysis.
Am J Gastroenterol, 93 (1998), pp. 1131-1135
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
